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Abstract Laparoscopic, ultrasound-guided radiofrequency
ablation (RFA) is a new, FDA-cleared uterine sparing, outpa-
tient procedure for uterine fibroids. The procedure utilizes
recent technological advancements in instrumentation and im-
aging, allowing surgeons to treat numerous fibroids of varying
size and location in a minimally invasive fashion. Early and
mid-term data from multi-center clinical trials have demon-
strated safety and efficacy, with resolution or improvement of
symptoms and significant volume reduction. Re-intervention
rates for fibroid symptoms have been low. The procedure is
well tolerated with a typically uneventful and rapid recovery
requiring NSAIDs only for postoperative pain. While post
RFA pregnancy data are limited, the results are promising.
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Introduction
Uterine fibroids remain a major women’s health issue with
significant economic and reproductive impact. They occur in
almost 70 % of Caucasian women and in greater than 80 % of
African American women by age 50 [1]. Fibroids have long
been known to be the most common indication for hysterec-
tomy. In an analysis of new diagnoses of fibroids in U.S.
women with access to medical care, Cardozo estimated the
total direct and indirect 2010 cost of uterine fibroids (includ-
ing associated obstetrical complications) to be $5.89–$34.37
billion annually [2].
While 30 % or 12.3 million U.S. women between the ages
of 25 and 44 experience symptoms of fibroids [3], the number
of hysterectomies, myomectomies, and uterine artery emboli-
zation procedures total less than 250,000 annually [4]. This
large discrepancy may be due to factors such as culture, lim-
ited access to medical care, cost factors, and work-related
issues. More likely, the data indicates patient rejection of the
procedures offered. Radiofrequency ablation of fibroids was
developed to provide women with a new minimally invasive
option for fibroid treatment that is safe, effective, and uterine
conserving.
RFA Historical Events
The basic technique of RFAwas first described byD’Arsonval
in 1891 [5]. He showed that passage of a RF current through
tissue caused an increase in tissue temperature.
In 1910, Beer reported the treatment of bladder neoplasms
through a Bcauterizing cystoscope^ [6]. In 1911, Clark de-
scribed treatment of superficial malignant growths with oscil-
latory desiccation [7]. RF did not become widely used in
medicine until Cushing and Bovie introduced the Bovie knife
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[8] in 1928. Radiofrequency catheter ablation [9] was devel-
oped in the 1980s and initially utilized a direct current (DC)
between a catheter electrode and a cutaneous surface electrode
to treat tachyarrhythmias. Radiofrequency ablation subse-
quently supplanted DC ablation and is now widely adopted
and first line therapy for certain tachycardias.
Tumor destruction using RFA is a recent innovation. In
1990, McGahan et al. [10] and Rossi et al. [11] independently
reported production of coagulative necrosis using a proximal-
ly insulated electrode with an exposed tip. The insulation of
the proximal portion of the electrode allowed insertion deep
into tissue to produce a distal ablation at the tip. In 1993,
McGahan [12] utilized this technique to treat liver tumors in
humans. However, practical application of RFA was limited
by the diminutive ablation size and the elongated, oval shape
characteristic of a single electrode device. Various device
modifications ensued, including multi-electrode arrays, clus-
ter electrodes, internally cooled electrodes, pulsed RF appli-
cation, saline infusion during RFA, and techniques such as
pharmaceutical therapy and vascular occlusion to decrease
heat loss. [13–16]. Ablation diameters approaching 7 cm are
now achievable in some cases. Such advancements led to
successful treatment of osteomas and subsequent FDA clear-
ance of two systems, one in 2000 for the specific treatment of
non-resectable liver lesions and another in 2004 for non-
resectable liver tumors. The FDA has also cleared several
systems for metastatic bone lesions. In 2012, the FDA cleared
the Acessa System (Halt Medical, Inc., Brentwood, CA)
(Fig. 1) for Bablation of soft tissue including treatment of
symptomatic uterine fibroids under direct ultrasound
guidance.^Radiofrequency tumor ablation has been usedwith
varying success in a number of other sites including the lung,
kidney, adrenal, thyroid, breast, bone, thoracic neoplasms, and
uterus (endometrium, fibroid tumors) [17–23].
Principles of Radiofrequency Ablation
Radiofrequency ablation (RFA) is a form of hyperthermic
ablation, i.e., using elevated temperature to produce tissue
destruction. Heat may be applied by direct thermal conduction
as in endometrial ablation with heated fluid or by ultrasound
or electromagnetic (RF, laser, microwave) energy. RFA is the
specific process of applying energy in the form of an alternat-
ing current in the radio frequency range (between 3 kHz and
300 GHz). Medical procedures typically use frequencies be-
tween 450 to 500 kHz. Nerve stimulation does not occur dur-
ing RFA since stimulation of nerves occurs at frequencies
below 10 kHz [24]. RFA is generally predictable, reliable,
and effective, given an appropriate target tissue.
Broadly, a radiofrequency system consists of a generator,
an electrode, electrode return pads, and cables connecting
these elements. Typically, RF systems use either temperature
or impedance feedback control and are monopolar.
The generator produces a high frequency, low voltage, al-
ternating current that is transmitted via an electrode with an
insulated shaft. Placement of the electrode into a target tissue
results in transmission of the current through the tissue with a
particular point of entry. The current then travels to the elec-
trode return pads and back to the generator, completing the
circuit. Heat is produced by ionic (Na, K, Cl) movement (re-
sistive heating) within the cells adjacent to the exposed portion
of the electrode in response to the very rapid shifts in polarity
inherent with an alternating current. The heat produced then
spreads by simple thermal conduction, producing a volumetric
ablation through coagulative necrosis. The size and shape of
the ablation volume is determined by the temperature reached,
the length of time at that temperature, and the shape of the
electrode (i.e., single electrode, multiple electrodes in an array,
curved or straight electrodes). Additional factors influencing
ablations include tissue conductivity and the presence or ab-
sence of fluid collections or vascularity which act as Bheat
sinks.^
Human cells die nearly immediately at 60 °C. Achievement
of cell death requires longer exposure at lower temperatures
[25]. High temperatures are desirable to produce a larger ab-
lation volume in a shorter amount of time. However, temper-
atures greater than 100 °C produce local tissue charring and
vaporizationwhich cause lower current density and insulation,
decreasing both heat generation and conduction. This results
in potential cold areas and incomplete ablations.
Significantly, the interface between the return electrodes
and the body is another site of heat generation. As a result,
prolonged application of RF energy may potentially result in
skin burns near the leading edge of the return pads. Pads with
larger surface areas dissipate heat better and minimize the
temperature rise. Some RF systems include thermocouples
in the return pads to monitor skin temperature as a safety
feature.
Fig. 1 Acessa System consisting of deployable multi-electrode array and
RFA generator
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Development of RFA of Fibroids
The first reported application of RFA to treat uterine fibroids
was by Lee [26] in 2002. This initial report described treat-
ment from 1999 to 2001 of 52 patients with 197 myomas
ranging in size from 1 to 11 cm. He reported uterine volume
reductions of 36 and 41 % at 3 and 6 months, 12-month
symptom resolution rates of better than 90 %, and no intra-
or perioperative complications, readmissions, or re-interven-
tions. In 2005, Lee [27] reported the 3-year outcomes. Ninety-
four percent of patients were asymptomatic, with one cumu-
lative re-intervention for fibroid symptoms at 23 months. Lee
also launched a prospective trial in 2002 utilizing a radiofre-
quency ablation needle shaped in a starburst pattern (Starburst
XL, Rita Medical) and incorporated preoperative and postop-
erative evaluations using the Uterine Fibroid Symptom and
Health-Related Quality of Life questionnaire developed by
Spies [28]. In 2005, Lee initiated design of a new radiofre-
quency ablation system specifically to treat uterine fibroids.
This system, currently called the Acessa System, ultimately
received FDA clearance in 2012 for the treatment of uterine
fibroids.
In 2005, Bergamini et al. [29] reported a pilot study of RFA
of fibroids in 18 subjects without intraoperative ultrasound
guidance using the Rita Medical RFA system and Starburst
XL needle. They reported reductions in myoma volumes of
41.5, 59, and 77 % at 1, 3, and 6 months with significant
improvement in the symptom and quality of life scores at 3
and 6 months.
In 2007, Milic et al. [30] reported laparoscopic ultrasound-
guided RFA using the LaVeen Needle Electrode (Boston
Scientific, Natick, MA) in four patients with small, symptom-
atic fibroids. The procedure was not technically feasible in one
patient, and only one of the remaining three had symptomatic
relief at 7 months.
In the same year, Lee [31] reported 36-month data from a
prospective trial of 110 patients. He also reported the first
known pregnancy and delivery after RFA of fibroids. At 3,
12, and 36 months, uterine volume declined by 39, 50, and
46%, respectively. UFS-QOL symptom scores fell 67, 87, and
90 %.
In 2011, Garza et al. [32] published results of a feasibility
study using the Acessa procedure. Seventy-six myomas in 31
subjects were treated with statistically significant reductions in
uterine volume and UFS-QOL questionnaire scores. There
were no repeat treatments, repeat hospitalizations, or device-
related complications. These results were confirmed by
Robles et al. [33] in 2013.
In 2013, Chudnoff et al. [34•] published the pivotal, multi-
center clinical trial results that lead to FDA clearance of the
Acessa System in 2012. The study was a prospective multi-
center international trial of 137 subjects with documented fi-
broids and menstrual blood loss between 150 and 500 mL.
Baseline MRI was used to establish fibroid number and size
and to exclude adenomyosis and type 0 submucosal myomas.
The three primary end points were volume of menstrual bleed-
ing at 12 months compared to baseline, surgical re-
intervention rate for heavy menstrual bleeding at 12 months,
and device and procedure-related adverse events within
12 months. Secondary endpoints were uterine volume mea-
surements, UFS-QOL scores, overall treatment evaluation
scores, and general health outcome scores at 12 months.
Menstrual blood loss fell in 81.9 % of subjects with a decrease
of at least 50 % in 40.2% of subjects and 22 % in 67.7 %.
There was one surgical re-intervention for persistent bleeding
and one serious adverse event. Total mean myoma volume
decreased 45.1 % from baseline. Ninety-four percent of sub-
jects were satisfied with their treatment.
In 2014, Berman et al. [35•] reported the three-year find-
ings of the same clinical trial. The cumulative re-intervention
rate for fibroid symptoms was 11 %. Seven of the fourteen
patients who had another procedure were found to have
adenomyosis. All subscale UFS-QOL scores and all health
state scores remained stable compared to one-year results in-
dicating durability.
Brucker et al. [36•] reported in 2014 the result of a random-
ized, prospective clinical trial evaluating RFA of fibroids with
the Acessa System and laparoscopic myomectomy. Twenty-
five patients were treated in each group. Operative blood loss
and hospital stay were both statistically significantly lower in
the RFA group. Ninety-eight percent of fibroids visualized
intra-operatively by laparoscopic ultrasound were treated in
the RFA group versus 80.3 % in the myomectomy group.
The operative time was also lower in the RFA group.
A randomized clinical trial comparing RFA of fibroids,
laparoscopic myomectomy, and uterine artery embolization
(TRUST study) [37] is currently underway using the Acessa
System.
Garza-Leal [38] reported a feasibility and safety study of
19 subjects and 20 fibroids in 2011 using a combined ultra-
sound and radiofrequency device (VizAblate, Gynesonics,
Redwood City, CA) via an intrauterine approach. Brölmann
et al. [39] in 2016 reported 12-month results with the same
device in 50 patients with 118 target fibroids (mean 2.4 fi-
broids/patient), fibroids with a mean fibroid diameter of
2.9 cm (range 1.0 to 6.9 cm). Ablations were achieved in
92 (78 %) of 118 target fibroids with an average reduction
in perfused volume of 68.1 and 67.4% at 3 and 12 months,
respectively. Sixty-four percent (59/92) of fibroids treated
were Type 1 or 2. Symptom severity scores decreased
55.1 % and menstrual pictogram scores decreased 53.8 %
by 12 months. Four patients (8 %) underwent re-
intervention by 12 months, and there were 34 adverse events
with two readmissions within 30 days of the procedure.
Satisfaction rate was 87.8 %. A pivotal multi-center clinical
trial was initiated in 2014.
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In 2015, a case report of intrauterine adhesion formation
after trans-vaginal, RFA of fibroids was published [40].
International interest in RFA of fibroids has extended to
Denmark [41], Korea [42, 43], China [44, 45], and Italy
[46]. Results of a trans-vaginal, extra-uterine approach with
trans-vaginal ultrasound have also been reported [42].
The Acessa Procedure Using the Acessa System
Physician qualifications:
1. Physicians should be experienced laparoscopic surgeons
and must be competent in the performance of and inter-
pretation of pelvic ultrasound.
Equipment requirements:
1. Standard laparoscopic tower (insufflator, camera box,
light source, printer)
2. Laparoscope 5 or 10 mm, zero degree
3. RFA generator, foot pedal, electrode dispersive pads,
cables
4. RFA handpiece (electrode)
5. Ultrasound machine with laparoscopic transducer (side
firing, variable frequency, either linear or sector, rigid)
6. Two video monitors placed adjacent to one another, one
for the laparoscopic image and one for the ultrasound
image.
RFA of fibroids is a laparoscopic procedure utilizing a 5-
mm port for the laparoscope and a second 10–12-mm port for
a laparoscopic, rigid, side-firing ultrasound transducer. The
author prefers patients to be in the dorsal position with a
single-tooth tenaculum applied to the cervix to manipulate
and stabilize the uterus. The RFA handpiece is inserted percu-
taneously through a 2-mm skin incision and directed into each
myoma with laparoscopic and ultrasound guidance.
Ultrasound is utilized to verify appropriate placement of the
device within each myoma. The deployable electrode array is
generally used for ablations exceeding 2 cm and is retracted at
the completion of the ablation. Coagulation of the track is then
performed with withdrawal of the handpiece. Irregular myo-
mas and those with diameters 4 cm and greater often require
multiple overlapping ablations in order to ensure adequate
ablation of the myoma periphery.
After ablation, myomas are not replaced by fibrous tissue
but gradually reabsorbed by the surrounding myometrium.
Complete myoma reabsorption is common with medium- to
small-sized myomas. The likelihood of complete reabsorption
is dependent upon the completeness of ablation, time, and the
myoma location.
Pregnancy Data
As of the date of this writing, documentation exists of 15
pregnancies in 13 patients yielding 13 live births after RFA
of fibroids. Fourteen pregnancies occurred in 12 patients after
laparoscopic, ultrasound-guided RFA and one pregnancy oc-
curred in a patient who underwent trans-uterine RFA. In the
laparoscopic group there were 12 viable, term infants and 2
first trimester spontaneous abortions. The age of two women
who underwent spontaneous abortion was 38 and 41 years at
treatment. The overall average age of the 14 women who had
laparoscopic RFA of fibroids was 35.7 yrs. The average inter-
val between the RFA of fibroids and first postoperative con-
ception was 7.7 months. Two women had two pregnancies
each post RFA. Of the 13 births, 8 were cesarean deliveries
and 5 were vaginal deliveries.
Additional pregnancy data will no doubt become available
over time. Since RFA of fibroids causes minimal myometrial
damage, RFA clinical trials such as the University of
California Ultra Study and the ongoing TRUST randomized
clinical trial allow inclusion of subjects who wish to conceive
after treatment. A German clinical trial is also underway
which is evaluating obstetrical outcome after RFA of fibroids
as its primary endpoint.
Clarifying Misconceptions About RFA of Fibroids
New procedures, being new, are inherently susceptible to mis-
understanding and misinterpretation because published data
from rigorous clinical studies remain largely unknown for a
period of time. The following myths are at times encountered
by the author and merit attention.
1. RFA of fibroids is the same procedure as myolysis.
The term myolysis may be broadly interpreted as a proce-
dure that destroys muscular tissue. In this regard, RFA of
fibroids could be called a form of myolysis. However, the
former procedure known as myolysis was very different in
how it was performed and in its effects upon the uterus and
fibroids.
Donnez et al. [47] reported using a Nd:YAG laser placed
hysteroscopically to treat submucosal myomas (Donnez).
Goldfarb [48] reported the first U.S. series using the
Nd:YAG laser laparoscopically and subsequently reported
using bipolar needles to repeatedly pierce and coagulate my-
omas and their peripheral vessels [49]. Unfortunately, these
techniques caused serosal and myometrial damage, resulting
in adhesion formation, subsequent uterine rupture in pregnan-
cy, and fetal loss [50, 51]. Elective cesarean section was rec-
ommended for those pregnancies that reached term.
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In contrast, RFA of fibroids was designed to volumetrically
ablate fibroids with very minimal damage to myometrium and
serosa. The insulated shaft allows treatment of fibroids deep
within the myometrium without ablation of proximal
myometrium. Electrode insertion does result in a needle track
several millimeters in width and a serosal puncture. If exces-
sive coagulation of the needle track is avoided, myometrial
and serosal damage should be minimal.
For this reason, in pregnancies after RFA, vaginal deliver-
ies have been permitted by some providers. Moreover, in the
author’s experience, in cases where RFA of fibroids was the
sole procedure performed, evaluation at subsequent proce-
dures do not reveal pelvic or abdominal adhesions.
Similarly, in the limited number of pregnancies after RFA,
serial ultrasound evaluations during pregnancy and palpation
and inspection at cesarean section have not revealed the pres-
ence of myometrial thinning or Buterine windows^ at ablation
sites. Nonetheless, at this time, the data regarding post RFA
pregnancies is still very limited and a larger clinical experience
is needed before definitive recommendations can be made.
2. Only fibroids that are submucosal cause heavy menstrual
bleeding.
In the pivotal phase three multi-center trial reported by
Chudoff et al. in 2013, all study subjects had uterine fibroids
and a baseline menstrual blood loss between 160 and 500 mL
based on hemoglobin measurement from catamenial products
by the alkaline hematin method. In a retrospective analysis of
this prospective trial, Galen et al. [52•] reported that only
48.4 % of subjects (59 of 122 who submitted catamenial prod-
ucts at 12 months) had one or more submucosal myomas.
Moreover, in the 51.6 % of subjects without submucosal fi-
broids, RFA of fibroids decreased menstrual bleeding 31.8 %
compared to baseline. While additional studies are needed,
this evidence strongly suggests that intramural myomas con-
tribute to heavy menstrual bleeding and that heavy menstrual
bleeding in patients with fibroids does in fact occur in the
absence of submucosal leiomyomas.
3. With RFA of fibroids, the Bproblem is the recurrence
rate.^
In 2014, Berman et al. reported data on 104 subjects who
had 36-month data post RFA of fibroids. The cumulative re-
intervention rate was 11 %. These data compare favorably
with that of laparoscopic myomectomy and uterine artery
embolization.
Within the group of subjects who had additional proce-
dures because of excessive menstrual bleeding, pathology, or
additional magnetic resonance imaging studies identified
adenomyosis in seven subjects. If these subjects had been
excluded (suspected adenomyosis by baseline MRI was an
exclusion criteria in the study), the re-intervention rate would
have actually been 5 %.
In addition, patient reported data (Uterine Fibroid
Symptom and Health-Related Quality of Life questionnaire)
were durable, demonstrating stability of the significant im-
provement in symptom scores compared to baseline at 12,
24, and 36 months.
4. Disadvantages of the Halt System include additional per-
cutaneous skin incisions, its treatment of one fibroid at a
time (<8 cm diameter), and its ablation of fibroids central-
ly while fibroids grow peripherally.
The skin incisions required when performing RFA of fi-
broids is one 5-mm incision for a 5-mm laparoscope, a 10–
12-mm incision for the laparoscopic ultrasound transducer,
and then a variable number of 2-mm incisions for percutaneous
placement of the electrode handpiece. The novice will often
require 3 to 4, 2 mm incisions whereas with greater experience,
these may be limited to one or two. The incision requirement
(two trocar sites) is approximately 50 % of traditional laparo-
scopic hysterectomy or laparoscopic myomectomy.
The clinical investigators participating in the multi-center,
pivotal phase three clinical trial reported by Chudnoff et al.
had very limited or no prior experience with RFA of fibroids.
Therefore, practical considerations and concern for patient wel-
fare demanded limitations on the number, size, and overall vol-
ume of fibroids. The existence of these limitations is not an
indication that uteri with fibroids of greater size or number
cannot or should not be treated. Indeed, the experience and
ability of the surgeon is a limiting factor in all procedures.
Using RFA, the author commonly treats fibroids 10–15 cm in
diameter and frequently treats uteri that are 20–26weeks in size.
As a general rule, fibroids of 1.5 cm in diameter do not
require deployment of the electrode array to ablate the myoma
periphery. Fibroids between 2 and 3.5 cm that are roughly
spherical should be treated by inserting the tip of the RFA
handpiece in the midline of the fibroid and directed toward the
center. Appropriate deployment of the electrode array will result
in treatment of the myoma periphery. In fibroids ≥4 cm in di-
ameter, multiple eccentric ablations are generally required with
the goal of treating the periphery of the myoma, not the center.
5. RFA can treat only a limited number of fibroids in certain
locations.
As in all procedures, greater experience and instruction in-
creases skill level and ability. Ideally, initial cases should be
limited to those with one to three medium-sized fundal myomas.
The author currently averages approximately 15 myomas per
case (range 1 to 45). With experience and additional training,
greater numbers in more challenging locations may be treated.
In terms of location, one of the advantages of RFA of fibroids is
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the eventual ability to treat myomas located in sites traditionally
regarded as high-riskwith safety and relative ease. Suchmyomas
include cervical, broad ligament, and round ligament myomas.
6. RFA damages the endometrium.
The basic premise of RFA of fibroids is to treat as much of
each myoma as possible and to spare non-fibroid tissue. The
procedure and instrumentation has been designed to allow
surgeons to accomplish this objective. With adherence to the
standard protocol for treatingmyomas, damage to endometrial
tissue should be minimal or absent. For example, posterior
myomas are treated by entering the uterus through the serosa
of the posterior uterine wall. This laparoscopic approach al-
lows direct access to the myoma avoiding entering or passing
through the endometrial cavity. In contrast, trans-cervical hys-
teroscopic approaches using mechanical dissection or radio-
frequency ablation necessitate cervical dilatation and at least
some degree of endometrial damage.
Experienced surgeons commonly treat type 1 and type 2
[53] submucosal myomas (greater than 50 % and less than
50 % intracavitary, respectively). It is recommended that type
0 myomas (100 % intracavitary) be removed via hysteroscop-
ic myomectomy.
Conclusions
RFA of fibroids has proven to be safe, versatile, and effective in
reducing or eliminating symptoms related to uterine fibroids. It
is effective in treating fibroids of various sizes and number in a
single setting. Recovery is rapid and usually uneventful with
mild postoperative pain. Return to work frequently occurs by
postoperative day four. Moreover, the potential for RFA of fi-
broids to produce health care savings is significant. Rapid return
to work, a low re-intervention rate, and perhaps a lower elective
cesarean rate compared to myomectomy are positive factors in
this regard. Greater experience with pregnancy outcomes after
RFA of fibroids will provide valuable data and will ultimately
influence the adoption of this minimally invasive treatment.
Finally, as with all new procedures, a proper understanding of
the procedure, adequate training, and knowledge of one’s surgi-
cal abilities are essential to maximizing patient outcomes.
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